Les Laboratoires Servier
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Les Laboratoires Servier
ASCO Preview: Five Top Late-Breakers To Watch For
AstraZeneca plans to unveil multiple major data packages, while Servier reveals much-anticipated results in glioma, and ImmunoGen and Novartis will present key pivotal data in women’s cancers.
Double Whammy For Merck And Eisai’s Keytruda/Lenvima Combo In Solid Tumors
The partners’ combination of Keytruda and Lenvima has missed the mark in two pivotal trials in melanoma and colorectal cancer, leading to one trial discontinuation and dashing hopes for important label expansions.
InflaRx Looks Ahead To Late 2023 Commercial Sales For COVID-19 Antibody
The price will be more expensive than prior COVID-19 antibodies, reflecting its target to critically ill patients who are hospitalized.
Servier’s Oncology Strategy Pays Off As Vorasidenib Hits Bullseye In Pivotal Glioma Trial
The French firm’s vorasidenib, obtained via a 2020 deal with Agios, has met the primary endpoint in a pivotal glioma trial, according to interim data, validating its strategic focus on the oncology space.
- Generic Drugs
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
- Biogaran SAS
- Egis Pharmaceuticals plc
- Servier BioInnovation
- Symphogen A/S
- Servier Pharmaceuticals, LLC.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.